Physician profile
Dharmendra Bhaskaran
NPI 1023289121
$282.35
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $71.99 | 2019 | |
| Novo Nordisk INC | $47.06 | 2019 | |
| Merck Sharp & Dohme LLC | $23.59 | 2019 | |
| Amgen INC. | $20.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.29 | 2019 | |
| Genentech USA, INC. | $17.26 | 2019 | |
| Astellas Pharma US INC | $15.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.58 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.15 | 2019 | |
| Amarin Pharma, INC. | $13.67 | 2019 | |
| Lilly USA, LLC | $12.53 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dharmendra Bhaskaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.